The global blood culture test market size is expected to reach USD 13.23 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 12.3% from 2024 to 2030. Owing to the increasing incidence of bloodstream infections as well as infectious diseases. Rising demand for advanced diagnostic techniques for the diagnosis of infectious diseases, such as sepsis, is also projected to drive growth. Recently, a substantial number of market players are focusing on the development of advanced tests with an aim to improve the efficiency of overall diagnostic procedures. Thus, many manufacturing companies are focusing on the development of advanced diagnostic instruments and consumables.
For instance, in May 2022, Cepheid confirmed that its Xpert Xpress CoV-2plus, a quick molecular diagnostic test for the identification of the infectious virus that causes COVID-19, has obtained the CE mark. Xpert Xpress CoV-2plus unites Xpert Xpress CoV-2/Flu/RSV plus as well as other PCRplus respiratory assessments in Cepheid’s diverse range of rapid, reliable, and implementable respiratory results. Such developments are likely to have a positive impact on the growth of the market during the forecast period. The introduction of various government initiatives pertaining to the prevention and control of infections is likely to propel the demand for blood culture tests.
Moreover, the authorities are also focusing on the implementation of strict guidelines to maintain the quality of diagnostics. For instance, in May 2022, CLSI released new National Blood Culture guidelines to prevent and reduce blood culture contaminations. Such regulations are also projected to accelerate the demand by 2030. A massive rise in the number of patients with COVID-19 infection throughout the world resulted in a significant increase in blood culture utilization, which greatly impacted the demand for automated instruments. For instance, in February 2022, Becton, Dickinson, and Company collaborated with ReturnSafe, an all-in-one software application for COVID-19 employee health, well-being, and adherence, to incorporate the BD Verito At-Home COVID-19 Test kits.
This consolidated solution, which uses the ReturnSafe and BD Veritor at-home COVID-19 Test, enables convenient and cost-effective administration of an enterprise's overall population. Key players are focusing on collaborations for the introduction of novel technologies. For instance, in September 2022, OpGen announced a strategic collaboration with FIND for rapid diagnosis of antimicrobial resistance (AMR) with the help of blood culture. Such developments are estimated to offer a favorable environment for market growth.
Request a free sample copy or view report summary: Blood Culture Test Market Report
The conventional technique segment captured the largest share in 2023 due to higher applications of this method in hospitals, individual clinical laboratories, as well as pathology laboratories
The consumables segment accounted for the largest revenue share in 2023 owing to the increased adoption of blood culture tests across all the applications
The automated systems segmentis anticipated to register the fastest CAGR from 2024 to 2030 owing to the increasing demand for technologically advanced diagnostic systems, improved accuracy, and minimal turn-around time
The molecular technology segment is anticipated to grow at the highest CAGR over the forecast period owing to the high demand for innovative products by hospitals and laboratories for the diagnosis of infectious diseases
The bacterial infections segment held the maximum share in 2023 owing to the high prevalence of bacterial infections and the adoption of these tests for bacterial disease diagnosis due to its proven success rate
The reference laboratories segment is anticipated to grow at the highest CAGR during the forecast period as there is a rise in outsourcing of blood tests by hospitals to reference laboratories
North America accounted for the highest revenue share in 2023 owing to massive investments in research & development
Grand View Research has segmented the global blood culture test market on the basis of product, technique, technology, application, end-use, and region:
Blood Culture Test Product Outlook (Revenue, USD Billion, 2018 - 2030)
Consumables
By Type
Bacterial Infections
Fungal Infections
Mycobacterial Infections
By Components
Blood Culture Media
Aerobic
Anaerobic
Fungi/Yeast
Others
Assay, Kits, and Reagents
Blood Culture Accessories
Instruments
By Type
Bacterial Infections
Fungal Infections
Mycobacterial Infections
By Components
Laboratory Equipment
Incubators
Colony Counters
Microscopes
Gram Stainers
Automated Blood Culture Systems
Software & Services
Bacterial Infections
Fungal Infections
Mycobacterial Infections
Blood Culture Test Technique Outlook (Revenue, USD Billion, 2018 - 2030)
Conventional
Automated
Blood Culture Test Technology Outlook (Revenue, USD Billion, 2018 - 2030)
Culture-based Technology
Molecular Technology
PCR
Microarray
PNA-FISH
Proteomic Technology
Blood Culture Test Application Outlook (Revenue, USD Billion, 2018 - 2030)
Bacterial Infections
Fungal Infections
Mycobacterial Infections
Blood Culture Test End-use Outlook (Revenue, USD Billion, 2018 - 2030)
Hospital Laboratories
Reference Laboratories
Others
Blood Culture Test Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Sweden
Denmark
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Mexico
Argentina
MEA
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Blood Culture Test Market
BD
Terumo Corporation
Bruker Corporation
bioMerieux
T2 Biosystems Inc.
Luminex Corporation
Abbott Laboratories
Siemens Healthineers AG
Danaher Corporation
F. Hoffmann-La Roche Ltd.
"The quality of research they have done for us has been excellent..."